Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to Buy at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Friday.

Other equities research analysts have also issued reports about the stock. Morgan Stanley lifted their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Leerink Partners lowered shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 13th. Finally, JMP Securities lifted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $67.11.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $74.93 on Friday. The stock has a market cap of $8.76 billion, a P/E ratio of 17.15, a price-to-earnings-growth ratio of 0.41 and a beta of 1.19. The company has a fifty day simple moving average of $62.80 and a 200-day simple moving average of $59.83. Halozyme Therapeutics has a 12-month low of $42.01 and a 12-month high of $75.46. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same period last year, the business earned $0.91 EPS. Halozyme Therapeutics’s revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $54,618,042.36. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares of the company’s stock, valued at $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,000 shares of company stock valued at $6,316,120 over the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics during the first quarter worth about $125,000. Bessemer Group Inc. grew its position in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 207 shares during the period. D. E. Shaw & Co. Inc. grew its position in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company’s stock worth $39,750,000 after buying an additional 524,802 shares during the period. Fifth Third Bancorp grew its position in Halozyme Therapeutics by 29.4% during the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company’s stock worth $639,000 after buying an additional 2,276 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 199.0% in the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 1,865 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.